Date: 1 Sept 2021
Your Name: Prof. Dame Caroline Watkins
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding,	NIHR	Research Grant
	provision of study materials, medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).		PREPARE: imPRoving End of life care Practice in stroke cARE. NIHR Programme Development Grant (PDG). Applicants: Thetford C, Lightbody L, Watkins C, Wee B, Clegg A, Burton C, Sprigg N, Jenkinson D, Forshaw D, Medina-Lara A, Prescott G, Brotherton A, Ogden M. Awarded: £149,980. 2020.
			PROmoting Stroke Pathway development EnhanCed by Technology (PROSPECT). Lancashire Teaching Hospitals NHS Foundation Trust (LTHTR) and HEIF (Research

			England). Applicant: Watkins C. Awarded £310,356. 2020.
			Covid-Liv Cohort Study: The Psychological and social
			impact of Covid 19. NIHR. COVID-19 Strategic Research
			Fund. Applicants: Bennett K, Corcoran R, Gabbay M,
			Giebel C, Shaw L, Watkins C, Reilly S, Cooper C, Lord K,
			Downs M, Komuravelli A, Rajagopal M, Rogers C,
			Gaughan A, Ward K, Shenton J, Tetlow H, Bell M, Eley R,
			Butchard S, Limbert S, Cannon J, Whittington R,
			_
			Callaghan S. Awarded £33,500. 2020.
			Stroke-Specific Education Framework (SSEF): Adoption
			and Development. (Title on Je-S form/GFU):
			Development and Maintenance of Stroke-Specific
			Education Framework (SSEF) (website). NHS Health
			Education England (HEE). Applicants: Watkins C, Nelson
			L, Miller C. Awarded £126,000. 2020.
			IMPROVIng Stroke care in India - Advancing The Instruct
			Operations and Network (IMPROVIS-ATION). NIHR
			Global Health Research Group on Improving Stroke Care
			at University of Central Lancashire. NIHR Global Health
			Research. Applicants: Watkins C, Georgiou R, Lightbody
			CE, Gibson J, Hackett M, Sutton C, Clegg A, Schroeder D,
			Sharma A, Forshaw D, Maulik P, Pandian J, Kalkonde Y,
			Gabbay M, Walker M, Radford K, Lindley R, Cadilhac D,
			Sanders C, Srivastava P, Middleton S, Sylaja PN. Awarded
			£493,257. 2020.
			NIHR Applied Research Collaboration (ARC) North West
			Coast (NWC). NIHR. Director: Gabbay M, Implementation
			Lead: Watkins C. Theme Leads: Marson T, Barr B, Hatton
			C, Clegg A, Gabbay M, Rogers S. Total grant awarded
			£9,000,000. 2019; UCLan awarded £3,085,000. Liverpool
			CCG co-funding £1,500,000. 2019-2024.
			Standardised Neurological OBservation Schedule for
			Stroke (SNOBSS). NIHR Doctoral Research Fellowship
			(DRF). Applicant: McLoughlin A; Supervisors: Lightbody
			CE, Watkins C, Olive P, Price C. Awarded £271,872. 2018.
			DECISIONS: DEvelopment of a Comprehensive
			Intervention to Support Individuals with anticoagulatiON
			to prevent Stroke. NIHR RfPB. Applicants: Gibson J,
			Watkins C, Georgiou R, Chauhan U, Joshi M, Rutter P,
			Banerjee A, Lowe D, Lane D, Cheng Hock T. Awarded:
			f141,084. 2018.
			Stroke in Sierra Leone (SISLE). NIHR Global Health
			Research Group on stroke at King's College London. NIHR
			Global Health Research. Applicants: Sackley C, Youkee D,
			Wolfe C, Rudd A, Peacock J, Fox Rushby J, McKevitt C,
			Leather A, Prince M, Watkins C, Langhorne P, Siegel FB.
2	Develties en l'arrest	Nene	Awarded: £1,998,986. 2018.
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		Chair, Trial Steering Committee (TSC) and Data Monitoring Committee (DMC) for COVID-NURSE: evaluation of the effects of a COVID-specific fundamental nursing care protocol compared to care as usual on experience of care for non-invasively ventilated patients in hospital with the SARS-CoV-2 virus: a randomised controlled trial. (Medical Research Council/UKRI Ref: COVO243; Grant no: MR/V02776X/1) (03.08.2020-until the project ends).Chair, Data Monitoring and Ethics Committee (DMEC) for Clinical and cost-effectiveness of an in-home personalised health promotion intervention enabling independence in older people with mild frailty ('HomeHealth'): A Randomised Controlled Trial NIHRMember, Study Steering Committee (SSC) for HTA Project: NIHR131227 - Predicting AF after Cardiac Surgery - the PARADISE Score A Clinical Prediction Rule for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. (05.08.2021-until the project ends)Member, International Scientific Advisory Committee for NIHR Global Health Research Group on Atrial Fibrillation Management (10.05.18-until the project ends)Member, Trial Steering Committee (TSC) for The Metoclopramide and selective oral decontamination for
			Metoclopramide and selective oral decontamination for Avoiding Pneumonia after Stroke (MAPS-2) Trial (NIHR HTA Ref: 14/49/154) (17.11.2016-until the project ends)

10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		Member, NIHR Advanced Fellowship Panel (29.10.2018- current). Committee Member, UK Swallowing Research Group (21.12.2018-to date) Member, International Stroke Rehabilitation and Recovery Alliance (ISRRA) [former International Stroke Recovery and Rehabilitation Roundtable 2 (SRRR 2)] (13.04.2018-to date) Chair, UK Stroke Forum (UKSF) (1.01.2019-31.12.2020) Chair, European Stroke Organisation Conference (ESOC) AHP Sub-Committee (2018-date) Member, European Stroke Organisation Conference Planning Group (ESOC) (06.06.2016 – to date).
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests		NIHR CLAHRC North West Coast (Deputy Director)(Co- app) NIHR CLAHRC NWC COMMITS project (Co-app) NIHR STIMULATE-ICP Grant (Co-app) NIHR REVERSE RfPB Project Grant (Co-app) NIHR DOCTORAL FELLOWSHIP Alison McLoughlin (Co- app) NIHR DOCTORAL FELLOWSHIP Clare Gordon (Co-app)

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:01/09/2021	
Your Name:Svetlana Tishkovskaya	
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 02/09/202
Your Name: Christopher Brown
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non- financial interests	None

 $\underline{\times}$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:31 st August 2021
Your Name:_Dr. Chris J Sutton
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NIHR Health Technology Assessment Commissioning Funding Committee Member	Member since January 2020. No payment to myself or institution (except for travelling expenses incurred).
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

_

Date: 31Aug2021
Your Name: Yvonne Sylvestre Garcia
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 31/08/2021 Your Name: Denise Forshaw Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Principal Clinical Trial Manager	Funded from award to provide senior oversight of study development, governance and set-up. Payment made to my institution.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	services Other financial or non-	None	
13	financial interests		

X_ I certify that I have answered every question and have not altered the wording of any of the questions on this Form.

Date:_31/08/2021	
Your Name:_GORDON PRESCOTT	
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre R	СТ
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from		National Institute of Health Research programme
	any entity (if not indicated		development grant on end of life care after stroke -
	in item #1 above).		applicant
			National Institute of Health Research grant for trial
			STIMULATE-ICP: Understanding long COVID to improve
			diagnosis, treatment and care – trial management group
			member

3	Royalties or licenses Consulting fees	None	National Institute of Health Research artificial intelligence grant - Real-world testing of an AI autonomous algorithm to rule-out normal chest X-ray exams and to fast track the diagnosis of those suspected lung cancer patients, with same-day CT - applicant Image: Comparison of the second s
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		I am on the Data Monitoring Committee of the CATHETER II trial of two washout policies (saline, citric acid) versus no washout policy in preventing catheter associated complications in adults living with long-term catheters. This is unpaid.
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I certify that I have answered every question and have not altered the wording of any of the questions on this form. X

Date: ___01-09-2021 Your Name: ___Lois Thomas Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	Other financial or non- financial interests	HS&DR commissioned Panel Member 2015-2019	

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:30 –Aug 2021	
Your Name:Christine Roffe	
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	NIHR	Research grant
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None	
	educational events		
6	Payment for expert testimony	None	
7		Nezz	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		 Chair of the trial steering committee for the Imaging cerebral neuro-inflammation in acute and chronic cerebrovascular disease: a predictor of outcome and biomarker for guiding treatment (IN-CVD) study funded by NIHR EME (CI: Karl Herholz). Member of the Data and Safety Monitoring Committee for the CAARBS feasibility study comparing a CCB versus ACEI/ ARB-based regime to target BP variability following TIA and minor ischaemic stroke funded by a BHF/ TSA Programme Grant (2016-) CI: T. Robinson (2017-). Member of the Data and Safety Monitoring Committee for the PROOF Study examining high dose oxygen treatment in patients with large vessel occlusion and acute ischaemic stroke funded by an EU Horizon 2020 grant (2016-). CI: S. Poli. Independent member of the Trial Steering Committee for the LACunar Intervention (LACI-2) Trial -2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar

		 stroke and progression of cerebral small vessel disease funded by a BHF grant. CI J Wardlaw (2016-) Independent member of the Trial Steering Committee for the Paramedic Acute Stroke Treatment Assessment (PASTA) Study Trial Steering Committee. CI C. Price (2015-2020) Co-applicant member of the Steering Group for the Right-2 study of pre-hospital treatment with GTN patches in acute stroke CI N. Bath (2015-2019). Co-applicant member of the Steering Group for the Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2) study, CIs N. Sprigg and P. Bath (2013-2019).
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Member of the James Lind Alliance Stroke Research Priority Setting Group (2020-) Member of the UK Biotechnology and Biological Sciences Research Council Future Leaders Funding board (2020-) Member of The Stroke Association Research Awards Panel (2019-) Member of the UK Swallowing research group (2019-) Member of the UK Stroke Forum Steering Group (2015-) Chair of the NIHR Hyperacute Stroke Research Centre Oversight Group (2015-) Stroke NIHR National Specialty Group Portfolio Lead for Acute Clinical Studies (2015-)

			Member of theNIHR HTA General Board (2017-2021) Member of the NIHR Stroke National Specialty Group (SNSG) (2015-2018)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	None	

____x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:31/08/21	
Your Name:_Joanne Booth	
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	NIHR	Co-investigator on ICONS II
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	NIHR HTA	Tibial nerve stimulation compared with sham to reduce incontinence in care home residents: ELECTRIC RCT. HTA 15/130/73
3	Royalties or licenses	None	

4	Consulting fees	None	
_			
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	None	
-			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	TSC member: CATHETER II study: Randomised Controlled Trial CompAring THE Clinical And CosTEffectiveness Of VaRious Washout Policies Versus No Washout Policy In Preventing Catheter Associated Complications In Adults Living With Long-Term Catheters. HTA 17/30/02
10	Loodorship or fiducion unde	Nana	
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options		
12	Description of a second second	Nese	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests		

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 31 st August 2021
Your Name: Kina Bennett
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	NIHR	HTA Research Grant – ICONS II
	provision of study materials,	NIHR	Programme Development Grant - PREPARE
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	NIHR	I4i Research Grant - MYPAD
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_x None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:__31 August 2021............. Your Name:_Professor Brenda Roe______ Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:02/09/2021
Your Name:Professor Bruce Hollingsworth
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

____ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_30/08/2021
Your Name:_Céu Mateus
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 01/12/21
Your Name: David Britt
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 01/12/21
Your Name: Cliff Panton
Manuscript Title: Identifying Continence OptioNs after Stroke (ICONS-II): a Pragmatic Multicentre RCT
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past None	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	ICONS II PPI Member	Expenses received for attending PPI Meetings (£494)
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.